Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Johnson & Johnson
JNJHealthcareGenerated Aug 19, 2026, 10:33 PM UTC
JNJ (Johnson & Johnson) analytical snapshot. Revenue grew +6.0% YoY to $94.19B. 5-year revenue CAGR +0.1%; 10y CAGR +3.0%. Net margin at 28.46% (expanding ▲). Market cap $658.89B at $273.41 per share. Trailing P/E 24.79, P/S 7.00, P/B 7.75. EV/Operating income ≈ 25.37 (EV $679.91B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 8 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 11, 2026. Latest quarterly report (10-Q) filed Jul 23, 2026. 9 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 11, 2026.
- Latest quarterly report (10-Q) filed Jul 23, 2026.
- 9 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Johnson & Johnson; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 9 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 11 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 8, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| Date | Form | Description |
|---|---|---|
| Aug 4, 2026 | 8-K | 8-K |
| Jul 29, 2026 | 8-K | 8-K |
| Jul 28, 2026 | 8-K | 8-K |
| Jul 15, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Apr 14, 2026 | 8-K | 8-K |
| Jan 21, 2026 | 8-K | 8-K |
| Oct 14, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" "substantial doubt" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 5 filing(s).
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 5 filing(s).
- R&D intensity declining: R&D as % of revenue fell from 2.1% to 0.1%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $88.82B | $94.19B | $5.37B | +6.0% |
| Gross profit | $61.35B | $63.94B | $2.59B | +4.2% |
| Operating income | $14.07B | $26.80B | $12.74B | +90.6% |
| Net income | $14.07B | $26.80B | $12.74B | +90.6% |
| Operating cash flow | $24.27B | $24.53B | $264.0M | +1.1% |
| Capex | $4.42B | $4.83B | $408.0M | +9.2% |
| Total assets | $180.10B | $199.21B | $19.11B | +10.6% |
| Total liabilities | $108.61B | $117.67B | $9.05B | +8.3% |
| Long-term debt | $32.40B | $41.44B | $9.04B | +27.9% |
| Cash & equivalents | $24.11B | $19.71B | $-4.40B | -18.2% |
| Stockholders equity | $63.28B | $74.02B | $10.74B | +17.0% |
| Inventory | $12.44B | $14.19B | $1.75B | +14.0% |
| Accounts receivable | $14.84B | $17.18B | $2.34B | +15.7% |
| R&D expense | $1.84B | $109.0M | $-1.73B | -94.1% |
| SG&A expense | $22.87B | $23.68B | $807.0M | +3.5% |
| Interest expense | $276.0M | $772.0M | $496.0M | +179.7% |
| Type | Concepts |
|---|---|
| Added | LossContingencyNumberOfPlaintiffs, PaymentsForLegalSettlements |
| Removed | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue, AdvertisingExpense, AllocatedShareBasedCompensationExpense, BusinessCombinationConsiderationTransferredLiabilitiesIncurred, CapitalExpenditureDiscontinuedOperations, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations, CommercialPaper, ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 5 | 0 | NEW |
| Substantial doubt about ability to continue | high | 5 | 0 | NEW |
| Impairment charge | medium | 5 | 8 | Ongoing |
| Restructuring | medium | 5 | 8 | Ongoing |
| Related party transactions | low | 5 | 4 | Ongoing |
Fundamentals
Revenue grew +6.0% YoY to $94.19B. 5-year revenue CAGR +0.1%; 10y CAGR +3.0%. Net margin at 28.46% (expanding ▲).
- Revenue grew +6.0% YoY to $94.19B.
- 5-year revenue CAGR +0.1%; 10y CAGR +3.0%.
- Net margin at 28.46% (expanding ▲).
- Gross margin 67.88%, operating margin 28.46%.
- Free cash flow margin 20.91% ($19.70B).
- Net income up ▲ +90.6% YoY.
- Debt/equity 0.49, current ratio 1.09, net debt $21.02B.
- Asset turnover 0.47 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $88.82B | +4.3% | 69.07 | 15.84 | 15.84 | $19.84B | — |
| 2025 | $94.19B | +6.0% | 67.88 | 28.46 | 28.46 | $19.70B | — |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2013 | $17.50B | — | — | 19.98% |
| Jun 30, 2013 | $17.88B | — | +2.1% | 21.44% |
| Sep 29, 2013 | $17.57B | — | -1.7% | 16.97% |
| Mar 30, 2014 | $18.11B | — | +3.1% | 26.09% |
| Jun 29, 2014 | $19.50B | — | +7.6% | 22.19% |
| Sep 28, 2014 | $18.47B | — | -5.3% | 25.72% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $658.89B at $273.41 per share. Trailing P/E 24.79, P/S 7.00, P/B 7.75. EV/Operating income ≈ 25.37 (EV $679.91B).
- Market cap $658.89B at $273.41 per share.
Price & Technicals
Price $273.41 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 79.15 (overbought).
- Price $273.41 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Moderate. Leverage debt/equity 0.49 (moderate). Liquidity current ratio 1.09 (adequate).
- Composite risk: Moderate.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 8
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Johnson & Johnson is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+6.0%** YoY to $94.19B..
Peer comparison
Defensive groupHow JNJ stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| Gilead Sciences GILD | 10 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Johnson & Johnson JNJ● you | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Merck & Co. MRK | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Zoetis Inc. ZTS | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Vertex Pharmaceuticals VRTX | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Costco Wholesale COST | -6 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Mondelez International MDLZ | -12 | Neutral |
| Kroger Co. KR | -13 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |